Mylan Adds To Inversion Surge With $5.3B Abbott Deal
Generic-drug maker Mylan Inc. said Monday it has agreed to acquire Abbott Laboratories' non-U.S. specialty and branded generics businesses for $5.3 billion in stock, intending to use the inversion deal to...To view the full article, register now.
Already a subscriber? Click here to view full article